Letteratura scientifica selezionata sul tema "Maladies inflammatoires intestinales – traitement médicamenteux"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Maladies inflammatoires intestinales – traitement médicamenteux".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Maladies inflammatoires intestinales – traitement médicamenteux":
Girardin, Marc, e Jean-Louis Frossard. "Place des [b]probiotiques[/b] dans le traitement des maladies inflammatoires intestinales". Revue Médicale Suisse 8, n. 352 (2012): 1674–78. http://dx.doi.org/10.53738/revmed.2012.8.352.1674.
Toussirot, Éric, Éric Houvenagel, Vincent Goëb, Damien Fouache, Antoine Martin, Philippe Le Dantec, Emmanuelle Dernis et al. "Développement de maladies inflammatoires intestinales au cours de traitement anti-TNF-α dans les rhumatismes inflammatoires. Étude nationale". Revue du Rhumatisme 79, n. 4 (luglio 2012): 323–29. http://dx.doi.org/10.1016/j.rhum.2011.12.004.
Spindler, L., E. Pommaret e V. de Parades. "Le traitement instrumental : « Qu’en reste-t-il aujourd’hui ? »". Côlon & Rectum 14, n. 1 (febbraio 2020): 15–20. http://dx.doi.org/10.3166/cer-2020-0120.
Bouchard, D., L. Tracanelli e F. Pigot. "Sahnan K, Tozer PJ, Adegbola SO, et al (2019) Developing a Core Outcome Set for Fistulising Perianal Crohn’s Disease Gut 68:226–38". Côlon & Rectum 14, n. 2 (maggio 2020): 100–101. http://dx.doi.org/10.3166/cer-2020-0135.
Belhocine, Mériem, Alissar Mourad, Aurélie Chapdelaine, Anne-Marie Mansour, Yves Troyanov e Maxime Doré. "Optimizing Thiopurine Therapy with a Xanthine Oxidase Inhibitor in Patients with Systemic Autoimmune Diseases: A Single-Centre Experience". Canadian Journal of Hospital Pharmacy 74, n. 4 (28 settembre 2021). http://dx.doi.org/10.4212/cjhp.v74i4.3199.
Tesi sul tema "Maladies inflammatoires intestinales – traitement médicamenteux":
Ferraro, Fabiana. "Enzyme-sensitive coatings for colon targeting : species-independent drug delivery systems". Electronic Thesis or Diss., Université de Lille (2022-....), 2023. http://www.theses.fr/2023ULILS035.
The aim of this thesis is to produce and characterize novel drug delivery systems for colon targeting.This project is part of the Interreg des 2 mers “Site-specific Drug Delivery” (https://www.interreg2seas.eu/fr/Site-Drug). The site-specific delivery of drugs to the colon presents major therapeutical advantages, for example in the treatment of inflammatory bowel diseases which required a local action. Conventional oral dosage forms lead to a fast and complete drug release in the stomach and small intestine and, generally, a systemic absorption into the bloodstream. Therefore, systemic concentrations of drugs and associated adverse effects can be considerable. Furthermore, the resulting concentrations of drug at the site of action (the inflamed colon) are low, resulting in low therapeutic efficacy. An ideal dosage form for the local treatment of colonic diseases should effectively prevent the release of the active substance in the stomach and small intestine. On the other hand, once the colon is reached, the release must begin and be controlled over time (including -if desired- a rapid and complete release). In the case of treatment of inflammatory diseases of the colon (e.g. Crohn's disease and haemorrhagic ulcerative colitis), the active ingredient is thus released at its site of action, offering optimal therapeutic effects and minimized side effects. Different types of drug delivery systems have been described in the literature aiming at site-specific release to the colon. Often, the drug is trapped in a polymeric matrix, or a drug reservoir (e.g. minigranules, capsules or tablets loaded with active ingredient) is coated with a polymeric film. The ideal polymers used for this purpose have low permeability for the drug in the upper part of the gastrointestinal tract, but become permeable as soon as the colon is reached. In order to allow such control delivery, various systems have been proposed, based in particular on: (i) changes in pH along the gastrointestinal tract, (ii) degradation of the polymer by enzymes preferentially located in the colon, or (iii) structural changes in the polymeric networks after a certain delay, such as the formation of cracks in low permeability films. Nevertheless, special attention should be paid because the pathophysiological conditions in the colon of patients with inflammatory bowel diseases may be significantly different from those in healthy subjects.(i) the pH of the contents of the gastrointestinal tract,(ii) the quality and quantity of microflora (secreting enzymes),(iii) transit times in different sections of the gastrointestinal tract. Thus, a galenic formulation which successfully releases an active ingredient in the colon of a healthy subject may fail in a patient. Similarly, the inter- and intra-individual variability of therapeutic effects can be considerable, if the dosage form is not appropriately adapted to the pathological state. The objective of this thesis project is to develop new galenic forms targeting the release of the active ingredient in the colon and which are adapted to the pathological state. The release of the drug will be triggered by enzymes located in the colon, regardless of the pathological state.1. Methods. The systems were prepared by functional coating of microgranules loaded with 5-ASA as drug. These systems have been characterized physico-chemically in different media simulating the gastrointestinal tract, this includes in particular exposure to media containing stools from patients with inflammatory bowel diseases as well as stools from animal models of these diseases (TNBS rats) and dog stools (healthy) under anaerobic conditions, in collaboration with INSERM U995 (Dr. Christel Neut). The main characterization technique used concerns the study of the release kinetics of systems exposed to these different release media [...]
Homerin, Germain. "P2X7R, une innovation dans le traitement des maladies inflammatoires et du cancer". Thesis, Lille 2, 2017. http://www.theses.fr/2017LIL2S059.
During this PhD thesis, we studied the design, the synthesis and the evaluation of the potential activities against inflammation and cancer, of new ligands of the purinergic receptors P2X7 (P2X7R). This work results from previous studies in the pharmacochemistry laboratory of HEI and from the reviewing of the scientific literature and has resulted in the creation of more than 100 originals compounds. These were tested on the P2X7R with the hope of providing new treatments for inflammatory bowel diseases (IBDs) and some forms of cancers.IBDs are crippling diseases and an estimated 200000 people sufferer from them in France. As of yet, no effective treatment exists, and current therapies only focus on suppressing symptoms to give patients better quality of life, without curing them. However, the development of potential new treatments is on-going, in particular with the development of new P2X7R ligands.P2X7R are part of the purinergic signalling system. They belong to the super-family of ion-channels. Recent in vivo and in vitro studies are showing the implication of P2X7R in many biological pathways, including inflammation and cancer mechanisms. P2X7R are responsible for the liberation of interleukins and so, they take part in the inflammatory process of IBD’s patients. Lastly, even though their role in cancer is not well understood many arguments exist in favour of using P2X7R antagonists and/or agonists and exploiting them for their implication in cell death
Sivelle, Coline. "Conception et production d’anticorps anti-TNFa non immunogènes pour le traitement des maladies inflammatoires". Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS603.
Efficacy of anti-TNFα antibodies is well known to be affected by their immunogenicity. Some patients developp anti-drug antibodies (ADA) which can elicit adverse effects and neutralize the therapeutic protein. Adalimumab (Humira®), which is the most used anti-TNFα, is reported to be immunogenic for more than 30% of patients in some diseases. T-cell epitopes that account for its immunogenicity are mostly carried by regions implied in the interaction with TNFα. In the present work, we propose to remove T-cell epitopes from the antibody sequence while maintaining its functionality.To undertake this issue, this PhD project uses Yeast Surface Display (YSD) to monitor the affinity of the biologic during the mutagenesis process. To do so, a comparison of different expression formats of antibody in YSD has been performed in order to define the format that will be used for the deimmunization method. Then, the strategy chosen to reduce immunogenicity is based on T-cell epitopes removal. First, it merges deep mutational scanning and in silico HLA II binding prediction to identify substitutions deleterious for HLA II/T-cell epitopes interaction while neutral for the function of the biologic. Secondly, these substitutions were combined to obtain libraries pre-enriched with functional sequences. Mutants with reduced immunogenic potential were then selected from these libraries. Several mutants of adalimumab with reduced immunogenicity potential according to HLA II binding prediction were identified and caracterized. All of them show an increased affinity for TNFα associated with an improvement of activity of at least two fold in comparison to adalimumab
Lemaire, Lucas. "Synthèse de composés pyrimido[5,4-d]- et pyrido[3,2-d]oxazoles originaux et développement de nouveaux agonistes potentiels des récepteurs CB2 pour le traitement des maladies inflammatoires chroniques de l’intestin". Thesis, Lille 2, 2015. http://www.theses.fr/2015LIL2S030.
Inflammatory bowel diseases (IBD), which two major forms are Crohn’s disease and ulcerative colitis, affect 2.2 million people in Europe. They are characterized by the inflammation of all or part of the digestive tract. Recent studies have shown that the endocannabinoid system has a beneficial role against inflammation of the gut through the CB2 receptor and the endocannabinoids. Our work focuses on the development of selective CB2 agonists for the treatment of IBD.First, two series of compounds were designed and synthesized around oxazole and isoxazole heterocycles. Different groups, known to be essential for CB2 agonist activity in previous series, were introduced on these heterocycles. These new compounds were evaluated for their pharmacological activity.Simultaneously, some original pyrimido[5,4-d]- and pyrido[3,2-d]oxazole compounds were synthesized starting from 5-amino-2-phenyloxazole-4-carbonitrile. Indeed, this pattern possesses an enaminonitrile system favorable to cyclisation. Firstly, the synthesis of these new bicycles was optimized. Then, pharmacophoric groups essential for the agonist CB2 activity were introduced to design new potential CB2 receptor agonists based on these bicycles
Bersuder, Émilie. "Cadhérine atypique MUCDHL et maladies inflammatoires chroniques intestinales : implication dans leur pathogénie, l'évolution cancéreuse et la réponse au traitement par les dérivés 5-aminosalicylés". Thesis, Strasbourg, 2019. http://www.theses.fr/2019STRAJ026.
The pathogenesis of Inflammatory Bowel Diseases (IBD) remains poorly understood and there is currently no curative treatment. In addition, patients with colonic IBD are at increased risk of colorectal cancer (CRC). The atypical cadherin MUCDHL could be involved in IBD. We studied the role of MUCDHL in the pathogenesis of IBD, as well as the molecular mechanisms that restore its expression. We have shown that MUCDHL expression is decreased in the inflammatory intestinal mucosa. In addition, 5-aminosalicylates, used to treat IBD and prevent associated CRC, increase its expression by stimulating PPAR-γ and CDX2 or by inhibiting β-catenin. In Mucdhl -/- mice, the absence of MUCDHL accelerates and amplifies colonic inflammation induced by Dextran Sodium Sulfate and delays mucosal repair. Our data show MUCDHL's involvement in the pathophysiology of IBD and suggest that it could be a therapeutic target of interest
Martin-Rodriguez, Omayra. "Evaluation des facteurs issus de l'efferocytose comme médicament innovant dans le traitement des maladies inflammatoires chroniques de l'intestin". Thesis, Bourgogne Franche-Comté, 2017. http://www.theses.fr/2017UBFCE011/document.
Inflammation is a natural body defence reaction in response to injuries. The clearance of apoptotic cells by macrophages is at the origin of a pro-resolving microenvironment composed of various soluble factors, allow the arrest of the inflammatory response and to initiate tissue repair. The resolution of inflammation is sometimes defective and contributes to the development of chronic inflammatory diseases, such as chronic inflammatory bowel disease (IBD), which include Crohn's disease (CD) and ulcerative colitis (UC). In this context, we propose to evaluate the therapeutic effect of these pro-resolving factors in the treatment of IBD. This factors derived from the culture of macrophages with apoptotic cells, and called SuperMApo (Supernatant issued from Macrophage Apoptotic cell culture) (Patent # WO2014106666-A1, 2013) contains pro-resolving factors similar to those found in the physiological process of inflammatory resolution, and which may be absent or ineffective in these patients.In this work, we have demonstrated the therapeutic effect of SuperMApo using two experimental models of colitis. To assess the relevance of these models to clinical practice, we have implemented flexible video endoscopy. The therapeutic effect of SuperMApo has been shown to decrease the clinical, endoscopic and histological score of colitis mice, accompanied by improved intestinal permeability and mucosal healing in vivo. This therapeutic effect is related in part to reprogramming of antigen presenting cells (APC), in particular cDC and macrophages, which exhibit less response to TLR ligands, promote induction of Treg and inhibit Th1 production. In addition, SuperMApo induces a marked tissue repair of the intestinal mucosa associated with activation of myofibroblasts, the active form of fibroblasts, and the epithelial intestinal cells (IEC). In particular, SuperMApo increases the migration, proliferation and wound healing properties of these two cell types. This effect depends in part on the growth factors contained in SuperMApo such as TGF-β, IGF-I and VEGF. Finally, preliminary results show that SuperMApo induces a repairing state on fibroblasts from patients with IBD. This opens widely the use of SuperMApo as a clinically approach to propose this new therapeutic option to refractory patients suffering from IBD
Tourteau, Aurélien. "Développement de nouveaux ligands sélectifs des récepteurs CB2 et de nouveaux inhibiteurs de la FAAH dans le traitement des maladies inflammatoires chroniques de l'intestin". Phd thesis, Université du Droit et de la Santé - Lille II, 2013. http://tel.archives-ouvertes.fr/tel-00992024.
Lucas-Andrzejak, Virginie. "Conception, synthèse et évaluation pharmacologique de nouveaux inhibiteurs de la Fatty Acid Amide Hydrolase (FAAH) potentiellement utilisables dans le traitement des Maladies Inflammatoires Chroniques de l'intestin (MICI)". Phd thesis, Université du Droit et de la Santé - Lille II, 2010. http://tel.archives-ouvertes.fr/tel-00590867.